CGP 3466 increases survival of cultured fetal dopaminergic neurons

Restorative Neurology and Neuroscience

Volumn 21, Issue 1-2, 2003, Pages 29-37

  Matarredona, Esperanza R ^a,b   Meyer, Morten ^a,c   Seiler, Rolf W ^a   Widmer, Hans R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF SEVILLE   (Spain)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Deprenyl; Glial cell line derived neurotrophic factor; Neural transplantation; Parkinson's disease; Rat; Tissue culture; Tyrosine hydroxylase

Indexed keywords

10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; DIBENZO[B,F]OXEPIN 10 YLMETHYLMETHYLPROP 2 YNYLAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; LACTATE DEHYDROGENASE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; FETUS; GRAFT SURVIVAL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROGLIA; MESENCEPHALON; NERVE CELL CULTURE; NERVE FUNCTION; NERVE GRAFT; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CELL COUNT; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CELLS, CULTURED; CORPUS STRIATUM; DOPAMINE; FETUS; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; L-LACTATE DEHYDROGENASE; MESENCEPHALON; NEURONS; OXEPINS; RATS; ROTATION; TIME FACTORS; TRANSPLANTS; TYROSINE 3-MONOOXYGENASE;

EID: 0038548433     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. M. Abercrombie, Estimation of nuclear population from microtome sections, Anat. Rec. 94 (1946), 239-247.
2. G. Andringa and A.R. Cools, The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey, J. Neural. Transm. Suppl. 60 (2000), 215-225.
3. G. Andringa, R.V. van Oosten, W. Unger, T.G. Hafmans, J. Veening, J.C. Stoof and A.R. Cools, Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra, Eur. J. Neurosci. 12 (2000), 3033-3043.
4. T. Alexi and F. Hefti, Trophic actions of transforming growth factor alpha on mesencephalic dopaminergic neurons developing in culture, Neuroscience 55 (1993), 903-918.
5. K.D. Beck, B. Knusel and F. Hefti, The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture, Neuroscience 52 (1993), 855-866.
6. G. Biagini, M. Zoli, K. Fuxe and L.F. Agnati, L-Deprenyl increases GFAP immunoreactivity in activated astrocytes in rat brain, NeuroReport 4 (1993), 955-958.
7. W. Birkmayer and P. Riederer, Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease, Adv. Neurol. 40 (1984), 475-481.
8. M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72 (1976), 248-254.
9. G.W. Carlile, R.M. Chalmers-Redman, N.A. Tatton, A. Pong, K.E. Borden and W.G. Tatton, Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer, Mol. Pharmacol. 57 (2000), 2-12.
10. E.D. Clarkson, W.M. Zawada and C.R. Freed, GDNF reduces apoptosis in dopaminergic neurons in vitro, Neuroreport 7 (1995), 145-149.
11. G. Ferrari, M.C. Minozzi, G. Toffano, A. Leon and S.D. Skaper, Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture, Dev. Biol. 133 (1989), 140-147.
12. L.I. Golbe, A.N. Lieberman, M.D. Muenter, J.E. Ahlskog, G. Gopinathan, A. Neophytides and R.C. Duvoisin, Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease, Clin. Neuropharmacol. 11 (1988), 45-55.
13. E.H. Heinonen, A.I. Markku and R.A.S. Lammintausta, Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites, Clin. Pharmacol. Ther. 56 (1994), 742-749.
14. E. Hitchcock, Current trends in neural transplantation, Neurol. Res. 17 (1995), 33-37.
15. G.U. Höglinger, J. Sautter, M. Meyer, C. Spenger, R.W. Seiler, W.H. Oertel and H.R. Widmer, Rat fetal ventral mesencephalon grown as solid tissue cultures: influence of culture time and BDNF treatment on dopamine neuron survival and function, Brain Res. 813 (1998), 13-322.
16. G.U. Höglinger, H.R. Widmer, C. Spenger, M. Meyer, R.W. Seiler, W.H. Oertel and J. Sautter, Influence of time in culture and BDNF pre-treatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease, Exp. Neurol. 167 (2001), 148-157.
17. M.A. Hynes, K. Poulsen, M. Armanini, L. Berkemeier, H. Philips and A. Rosenthal, Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures, J. Neurosci. Res. 37 (1994), 144-154.
18. B. Knusel, P.P. Michel, J. Schwaber and F. Hefti, Selective and non-selective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, and the insulin-like growth factors, J. Neurosci. 10 (1990), 558-570.
19. B. Knusel, J.W. Winslow, A. Rosenthal, L.E. Burton, D.P. Seid, K. Nikolics and F. Hefti, Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin-3, Proc. Natl. Acad. Sci. USA 88 (1991), 961-965.
20. J.H. Kordower, T.B. Freeman, B.J. Snow, F.J. Vingerhoets, E.J. Mufson, P.R. Sanberg, R.A. Hauser, D.A. Smith, G.M. Nauert, DP. Perl et al., Neuropathological evidence of graft survival and striatal reinnervation after transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease, N. Engl. J. Med. 332 (1995), 1118-1124.
21. E. Koutsilieri, T.-S. Chen, W.-D. Rausch and P. Riederer, Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium, Eur J. Pharmacol. 306 (1996), 181-186.
22. E. Kragten, I. Lalande, K. Zimmermann, S. Roggo, P. Schindler, D. Müller, J. van Oostrum, P. Waldmeier and P. Fürst, Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the anti-apoptotic compounds CGP 3466 and R-(-)-deprenyl, J. Biol. Chem. 6 (1998), 5821-5828.
23. U.K. Laemmli, Cleavage of structural proteins during assembly of the head of bacteriophage T4, Nature 277 (1970), 680-685.
24. O. Lindvall, Clinical application of neuronal grafts in Parkińson's disease, J. Neurol. 242 (1994a), 54-56.
25. O. Lindvall, G. Sawle, H. Widner, J.C. Rothwell, A. Björklund, D. Brooks, P. Brundin, R. Frackowiak, C.D. Marsden and P. Odin, Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease, Ann. Neurol. 35 (1994b), 172-180.
26. M.K. McMillian, L. Thai, J.S. Hong, J.P. O'Callagham and K.R. Pennypacker, Brain injury in a dish: a model for reactive gliosis, TINS 17 (1994), 138-142.
27. M. Meyer, E.R. Matarredona, R.W. Seiler, J. Zimmer and H.R. Widmer, Additive effect of glial cell line-derived neurotrophic factor and neurotrophin-4/5 on rat fetal nigral explant cultures, Neuroscience 108 (2001), 273-284.
28. M. Meyer, H.R. Widmer, B. Wagner, R. Guzman, L. Evtouchenko, R.W. Seiler and C. Spenger, Comparison of mesencephalic free-floating tissue culture grafts and cell suspension grafts in the 6-hydroxydopamine-lesioned rat, Exp. Brain Res. 119 (1998), 345-355.
29. M. Meyer, J. Zimmer, R.W. Seiler and H.R. Widmer, GDNF increases the density of cells containing calbindin but not of cells containing calretinin in cultured rat and human fetal nigral tissue, Cell Transplantation 8 (1999), 25-36.
30. C. Mytilineou, E.K. Leonardi, P. Radcliffe, E.H. Heinonen, S.K. Han, P. Werne, G. Cohen and C.W. Olanow, Deprenyl and desmethylselegiline protect mesencephalic cultures neurons from toxicity induced by glutathione depletion, J. Pharmacol. Exp. Ther 284 (1998), 700-706.
31. C. Mytilineou, P.M. Radcliffe and C.W. Olanow, L-(-)-Desmethylselegiline, a metabolite of selegiline, protects mesencephalic dopamine neurons from excitotoxicity in vitro, J. Neurochem. 68 (1997), 434-436.
32. A. Petersen, O. Hansson, M. Emgard and P. Brundin, Grafting of nigral tissue hibernated with tirilazad messylate and glial cell line-derived neurotrophic factor, Cell Transplantation 9 (2000), 577-584.
33. M. Revuelta, J.L. Venero, A. Machado and J. Cano, Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic ulgrostriatal system but fails to counteract axotomy-induced degenerative changes, Glia 21 (1997), 204-216.
34. C. Rosenblad, A. Martinez-Serrano and A. Bjorklund, Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts, Neuroscience 75 (1996), 979-985.
35. E. Roy and P.J. Bédard, L-Deprenyl increases survival of rat foetal nigral neurones in culture, NeuroReport 4 (1993), 1183-1186.
36. J. Sautter, M. Meyer, C. Spenger, R.W. Seiler and H.R. Widmer, Effects of combined BDNF and GDNF treatment on cultured dopaminergic midbrain neurons, NeuroReport 9 (1998), 1093-1096.
37. J. Sautter, J.L. Tseng, D. Braguglia, P. Aebischer, C. Spenger, R.W. Seiler, H.R. Widmer and A.D. Zurn, Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts, Exp. Neurol. 149 (1998), 230-236.
38. S.R. Sinclair, C.N. Svendsen, E.M. Tones, D. Martin, J.W. Fawcett and S.B. Dunnet, GDNF enhances dopaminergic cell survival and fiber outgrowth in embryonic nigral grafts, Neuroreport 7 (1996), 2547-2552.
39. C. Spenger, L. Studer, L. Evtouchenko, M. Egli, J.M. Burgunder, R. Markwalder and R.W. Seiler, Long term survival of dopaminergic neurons in free floating roller tube cultures of human fetal ventral mesencephalon, J. Neurosci. Methods 54 (1994), 63-73.
40. W.G. Tatton and R.M.E. Chalmers-Redman, Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration, Neurology 47(Suppl 3) (1996), S171-S183.
41. A. Vassault, Lactate dehydrogenase: ultraviolet method with pyruvate and NADH, in: Methods of enzymatic analysis, H.U. Bergmeyer, J. Bergmeyer and M. Grossl eds, 1983, pp. 118-126.
42. P.C. Waldmeier, A.A. Boulton, A.R. Cools, A.C. Kato and W.G. Tatton, Neurorescuing effects of the GAPDH ligand CGP 3466, J. Neural. Transm. Suppl. 60 (2000), 197-214.
43. P.C. Waldmeier, W.P. Spooren and B. Hengerer, CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease, Naunyn Schmiedebergs Arch. Pharmacol. 362 (2000), 526-537.
44. H.R. Widmer, F. Ohsawa, B. Knüsel and F. Hefti, Down regulation of phosphatidylinositol response to BDNF and NT-3 in cultures of cortical neurons, Brain Res. 614 (1993), 325-334.
45. D.M. Yurek, Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue, Exp. Neurol. 153 (1998), 195-202.